{
  "id": 122579,
  "title": "FT: AstraZeneca and Bristol-Myers Squibb plan $400bn merger",
  "url": "https://urgent.news/2026/08/04/ft-astrazeneca-and-bristol-myers-squibb-plan-400bn-merger",
  "topic": "business",
  "section": "Business",
  "published": "2026-08-04T08:04:34.000Z",
  "source": {
    "name": "Silicon Republic",
    "slug": "silicon-republic",
    "url": "https://www.siliconrepublic.com/business/astrazeneca-bristol-mysers-squibb-merger"
  },
  "original_language": "en",
  "account": "The Financial Times reports discussions continue over a potential $400bn merger between pharmaceutical giants AstraZeneca and Bristol-Myers Squibb. The combined company would rank as the world's fourth-largest pharmaceutical business. While talks have been ongoing for months, the partnership could still be abandoned or delayed. AstraZeneca's shares dropped over 6% on Monday, while Bristol-Myers Squibb shares rose slightly. AstraZeneca, valued at around $181.5bn, seeks to expand its US presence, its second largest business in the US now trading shares on the New York Stock Exchange. The company reported a 6% profit increase and plans to invest $1bn more in capital expenditure, aiming for $80bn in annual revenue by 2030. Bristol-Myers, at roughly $133bn, recently saw a 6% revenue growth in its US market. Both companies have operations in Ireland and are currently hiring there.",
  "summary": "Despite months-long discussions, talks could still fall apart, reports the Financial Times. Read more: FT: AstraZeneca and Bristol-Myers Squibb plan $400bn merger",
  "key_points": [
    "AstraZeneca and Bristol-Myers Squibb plan $400bn merger",
    "Combined company would be world's fourth-largest pharma business",
    "AstraZeneca seeks to expand US presence, Bristol-Myers grew 6% revenue in US"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}